Marc A. Shuman, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Marc A. Shuman, MD

Professor, Departments of Medicine and Urology, UCSF

shuman@medicine.ucsf.edu

Phone: (415) 476-2125 (voice)
Box 1270, UCSF
San Francisco, CA 94143-1270

View on UCSF Profiles

Cancer Center Membership

Program Member ยป Prostate Cancer

Education

University of Wisconsin, Madison Madison, WI, B.S., 1962, Philosophy/Chemistry
University of PA, Philadelphia Philadelphia, PA, Biology
Thomas Jefferson Medical College Philadelphia, PA, M.D., 1967, Medicine


Professional Experience

  • 1967-1968
    Intern, Pennsylvania Hospital, Philadelphia
  • 1968-1969
    Junior Assistant Resident, Hospital of the University of Pennsylvania, Philadelphia
  • 1971-1972
    Senior Resident, Department of Medicine, Hospital of the University of Pennsylvania, Phila.
  • 1972-1973
    Clinical Fellow, Division of Hematology-Oncology, Washington University, St. Louis, MO
  • 1973-1976
    Postdoctoral Fellow, Division of Hematology-Oncology, Washington University, St. Louis, MO
  • 1976-1981
    Assistant Professor of Medicine, University of California, San Francisco
  • 1981-1986
    Associate Professor of Medicine, University of California, San Francisco
  • 1986-present
    Professor of Medicine, University of California, San Francisco
  • 1989-present
    Chief of Hematology, Division of Hematology-Oncology, UCSF
  • 1992-1996
    Interim Director, Cancer Research Institute, UCSF
  • 1996-2004
    Associate Director, Cancer Research Institute, UCSF
  • 1997-2000
    Chief of Oncology, Division of Hematology-Oncology, UCSF
  • 1997-2007
    Associate Director for Program Development, UCSF Helen Diller Family Comprehensive Cancer Center
  • 1997-2007
    Director, Prostate Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center
  • 1997-present
    Executive Committee, UCSF Helen Diller Family Comprehensive Cancer Center
  • 1999-present
    Professor of Urology, University of California, San Francisco
  • 2005-present
    Clinical Director, California Institute for Quantitative Biomedical Research (QB3), San Francisco, CA

Honors & Awards

  • 1980
    Elected to American Society of Clinical Investigation
  • 1981
    Awarded Research Career Development Award, National Institutes of Health
  • 1989
    Elected to Association of American Physicians

Selected Publications

  1. EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nat Neurosci. 2015 Sep; 18(9):1236-46.
    View on PubMed
  2. WITHDRAWN: Enhanced Detection and Phenotypic and Karyotypic in Situ Characterization of Circulating Tumor Cells. Am J Pathol. 2014 Oct 17.
    View on PubMed
  3. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014 Feb 15; 20(4):1029-41.
    View on PubMed
  4. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51.
    View on PubMed
  5. Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev. 2012 Aug 15; 26(16):1780-96.
    View on PubMed
  6. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012 Feb 15; 18(4):1146-55.
    View on PubMed
  7. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res. 2012 Feb; 40(4):1695-707.
    View on PubMed
  8. Time-resolved single-step protease activity quantification using nanoplasmonic resonator sensors. ACS Nano. 2010 Feb 23; 4(2):978-84.
    View on PubMed
  9. The unfolded protein response during prostate cancer development. Cancer Metastasis Rev. 2009 Jun; 28(1-2):219-23.
    View on PubMed
  10. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res. 2009 Mar 15; 15(6):1989-97.
    View on PubMed
  11. Differential gene expression in central nervous system lymphoma. Blood. 2009 Jan 1; 113(1):266-7; author reply 267-8.
    View on PubMed
  12. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008 Jan 1; 26(1):96-105.
    View on PubMed
  13. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007 Apr 10; 25(11):1350-6.
    View on PubMed
  14. The epidemiology of prostate cancer--with a focus on nonsteroidal anti-inflammatory drugs. Hematol Oncol Clin North Am. 2006 Aug; 20(4):797-809.
    View on PubMed
  15. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006 May 1; 107(9):3716-23.
    View on PubMed
  16. Symposium on androgen action in prostate cancer. Cancer Res. 2004 Oct 1; 64(19):7178-80.
    View on PubMed
  17. Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med. 2004 Jan 26; 164(2):218-20.
    View on PubMed
  18. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol Chem. 2003 Feb; 384(2):257-66.
    View on PubMed
  19. Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate Cancer Prostatic Dis. 2003; 6(4):272-80.
    View on PubMed
  20. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003 Jan 15; 101(2):466-8.
    View on PubMed

Go to UCSF Profiles, powered by CTSI